{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.341","value":"-8.43"},{"groupId":"OG001","spread":"12.586","value":"0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.210","value":"-9.86"},{"groupId":"OG001","spread":"12.046","value":"1.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"Week 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.980","value":"-9.14"},{"groupId":"OG001","spread":"10.760","value":"1.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Week 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.204","value":"-10.29"},{"groupId":"OG001","spread":"13.047","value":"2.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"Week 28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.027","value":"-9.35"},{"groupId":"OG001","spread":"9.586","value":"0.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Week 40"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.403","value":"-8.63"},{"groupId":"OG001","spread":"9.334","value":"0.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Week 52"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.520","value":"-9.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 80"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.971","value":"-7.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 92"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.297","value":"-6.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 104"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.702","value":"-6.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 117"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.234","value":"-8.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 130"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.653","value":"-8.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 143"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.081","value":"-8.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 156"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.392","value":"-7.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 169"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.675","value":"-9.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 182"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.922","value":"-7.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 195"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.347","value":"-9.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 208"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.054","value":"-7.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 221"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.922","value":"-7.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 234"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.905","value":"-7.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 247"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"75"}],"units":"Participants"}],"description":"The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Ruxolitinib at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid","id":"OG000","title":"Ruxolitinib"},{"description":"Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"MEAN","populationDescription":"Full Analysis Set (FAS) included all participants to whom study treatment was assigned by randomization and had valid measurements for the outcome measure. Data after crossover for participants randomized to BAT are reported as separate outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 4, 8, 16, 28, 40, 52, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247","title":"Change From Baseline in Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)","type":"SECONDARY","unitOfMeasure":"Score on a scale"}